K. E. Truitt - Concepedia

Author

K. E. Truitt

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

K Truitt, K. E. Truitt, K. Truitt, Ken TRUITT, Ken Truitt

Publications

373

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Daiichi Sankyo (United States)

About

K. E. Truitt is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and drug safety.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	316
2	Cell Biology	2	2	59
3	Diabetes	2	2	74
4	Natural Sciences	1	1	33
5	Biochemistry	1	1	33

K. E. Truitt

Publications

373

Citations

H-Index

Page 1

	Year	Citations
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis Thomas J. Schnitzer, K. E. Truitt, Roy Fleischmann, Clinical Therapeutics Drug SafetyRheumatologyRheumatoid DisorderMedicineRheumatic Diseases	1999	137
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis K. E. Truitt, Rhoda Sperling, W. H. Ettinger, Aging Clinical and Experimental Research Advanced Elderly PatientsChronic Musculoskeletal ConditionClinical TrialsOsteoarthritisNon-operative Management	2001	79
A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis Piet P. Geusens, K. E. Truitt, P.P. Sfikakis, Scandinavian Journal of Rheumatology	2002	46
Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes Allison B. Goldfine, Vivian Fonseca, Michelle R. Jones, Hormone and Metabolic Research Drug SafetyMetabolic SyndromeAdverse EventsDiabetes ManagementCardiovascular Disease	2009	41
Role of p85 subunit of phosphatidylinositol-3-kinase as an adaptor molecule linking the insulin receptor to insulin receptor substrate 1. Víctor Sánchez‐Margalet, I D Goldfine, K. E. Truitt, Molecular Endocrinology Insulin ReceptorInsulin SignalingMolecular PharmacologyReceptor Substrate 1Signaling Pathway	1995	33
Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK Spencer B. Gibson, K. E. Truitt, Yiling Lu, Biochemical Journal Adaptive Immune SystemT-regulatory CellAccessory ReceptorImmunologyImmune Regulation	1998	26
A 26‐week, placebo‐ and pioglitazone‐controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus Hao-Yu Chou, K. E. Truitt, James B. Moberly, Diabetes Obesity and Metabolism	2012	11

Page 1